351 related articles for article (PubMed ID: 22690943)
1. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.
Kothny W; Shao Q; Groop PH; Lukashevich V
Diabetes Obes Metab; 2012 Nov; 14(11):1032-9. PubMed ID: 22690943
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial.
Lukashevich V; Schweizer A; Shao Q; Groop PH; Kothny W
Diabetes Obes Metab; 2011 Oct; 13(10):947-54. PubMed ID: 21733061
[TBL] [Abstract][Full Text] [Related]
3. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
[TBL] [Abstract][Full Text] [Related]
4. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
5. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
6. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Bosi E; Camisasca RP; Collober C; Rochotte E; Garber AJ
Diabetes Care; 2007 Apr; 30(4):890-5. PubMed ID: 17277036
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
[TBL] [Abstract][Full Text] [Related]
9. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
Rosenstock J; Kim SW; Baron MA; Camisasca RP; Cressier F; Couturier A; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
[TBL] [Abstract][Full Text] [Related]
11. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
12. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Rosenstock J; Baron MA; Dejager S; Mills D; Schweizer A
Diabetes Care; 2007 Feb; 30(2):217-23. PubMed ID: 17259484
[TBL] [Abstract][Full Text] [Related]
13. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
Panina G
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():32-9. PubMed ID: 17877545
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data.
Hoste J; Daci E; Mathieu C
Acta Clin Belg; 2014 Jun; 69(3):171-6. PubMed ID: 24820924
[TBL] [Abstract][Full Text] [Related]
15. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.
Kothny W; Foley J; Kozlovski P; Shao Q; Gallwitz B; Lukashevich V
Diabetes Obes Metab; 2013 Mar; 15(3):252-7. PubMed ID: 23039321
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
Scherbaum WA; Schweizer A; Mari A; Nilsson PM; Lalanne G; Jauffret S; Foley JE
Diabetes Obes Metab; 2008 Aug; 10(8):675-82. PubMed ID: 18248490
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats.
Murase H; Kuno A; Miki T; Tanno M; Yano T; Kouzu H; Ishikawa S; Tobisawa T; Ogasawara M; Nishizawa K; Miura T
Cardiovasc Diabetol; 2015 Aug; 14():103. PubMed ID: 26259714
[TBL] [Abstract][Full Text] [Related]
19. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
20. The scientific evidence: vildagliptin and the benefits of islet enhancement.
Mathieu C
Diabetes Obes Metab; 2009 May; 11 Suppl 2():9-17. PubMed ID: 19385979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
